<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34665352</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Duplication of exons 15 and 16 in Matrin-3: a phenotype bridging amyotrophic lateral sclerosis and immune-mediated disorders.</ArticleTitle><Pagination><StartPage>1419</StartPage><EndPage>1421</EndPage><MedlinePgn>1419-1421</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-021-05669-2</ELocationID><Abstract><AbstractText>Mutations in Matrin-3 (MATR3) gene have been described in ALS, suggesting a role for this gene in the disease pathogenesis. While most of MATR3 mutations are point mutations, here we report the first case of ALS associated with duplication in exons 15 and 16. The patient presented with limb-onset ALS and a complex past medical history because of Sj&#xf6;gren syndrome, antiphospholipid antibodies positivity, polyallergies, endometriosis, aldosterone-secreting adrenal cortical adenoma, congenital vesicoureteral reflux, and right breast hypoplasia. We discuss MATR3 effect in ALS and the role of this previously undescribed mutation in this peculiar ALS phenotype associated with systemic autoimmunity involvement.</AbstractText><CopyrightInformation>&#xa9; 2021. Fondazione Societ&#xe0; Italiana di Neurologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caputo</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zucchi</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5604-4529</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy. elibettizucchi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Experimental PhD Program, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gianferrari</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonini</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amedei</LastName><ForeName>Amedeo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niccolai</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gellera</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico 'Carlo Besta', Via Celoria 11, 20133, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pensato</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico 'Carlo Besta', Via Celoria 11, 20133, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Grant FRRB 2015-0023</GrantID><Agency>fondazione per la ricerca biomedica</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C518587">MATR3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034521">Nuclear Matrix-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034521" MajorTopicYN="N">Nuclear Matrix-Associated Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Congenital malformation</Keyword><Keyword MajorTopicYN="N">Immune checkpoint</Keyword><Keyword MajorTopicYN="N">Immune response</Keyword><Keyword MajorTopicYN="N">Matrin-3</Keyword><Keyword MajorTopicYN="N">Next-generation sequencing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>19</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34665352</ArticleId><ArticleId IdType="doi">10.1007/s10072-021-05669-2</ArticleId><ArticleId IdType="pii">10.1007/s10072-021-05669-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Marangi G, Lattante S, Doronzio PN, Conte A, Tasca G, Monforte M et al (2017) Matrin 3 variants are frequent in Italian ALS patients. Neurobiol Aging 49:218.e1-218.e7. https://doi.org/10.1016/j.neurobiolaging.2016.09.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.09.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE et al (2014) Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci 17:664&#x2013;666. https://doi.org/10.1038/nn.3688</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3688</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId><ArticleId IdType="pmc">4000579</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro M, Venkateswaran N, Peters ST, Deyle DR, Bower M, Koob MD et al (2020) Case report: early-onset behavioral variant frontotemporal dementia in patient with retrotransposed full-length transcript of Matrin-3 variant 5. Front Neurol 11:600468. https://doi.org/10.3389/fneur.2020.600468</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.600468</ArticleId><ArticleId IdType="pubmed">33408686</ArticleId><ArticleId IdType="pmc">7779795</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehringer A, Garcia-Mansfield K, Singh G, Bakkar N, Pirrotte P, Bowser R (2017) ALS associated mutations in Matrin 3 alter protein-protein interactions and impede mRNA nuclear export. Sci Rep 7:14529. https://doi.org/10.1038/s41598-017-14924-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14924-6</ArticleId><ArticleId IdType="pubmed">29109432</ArticleId><ArticleId IdType="pmc">5674072</ArticleId></ArticleIdList></Reference><Reference><Citation>Synofzik M, Smets K, Mallaret M, Di Bella D, Gallenm&#xfc;ller C, Baets J, Schulze M, Magri S, Sarto E, Mustafa M et al (2016) SYNE1 ataxia is a common recessive ataxia with major non-cerebellar features: a large multi-centre study. Brain 139:1378&#x2013;1393</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww079</ArticleId><ArticleId IdType="pubmed">27086870</ArticleId><ArticleId IdType="pmc">6363274</ArticleId></ArticleIdList></Reference><Reference><Citation>Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206:3015&#x2013;3029. https://doi.org/10.1084/jem.20090847</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20090847</ArticleId><ArticleId IdType="pubmed">20008522</ArticleId><ArticleId IdType="pmc">2806460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ok&#x15f;a&#x15f;o&#x11f;lu B, Hepokur C, Misir S, Yildiz C, S&#xf6;nmez G, Yanik A (2021) Determination of PD-1 expression in peripheral blood cells in patients with endometriosis. Gynecol Endocrinol 37:157&#x2013;161. https://doi.org/10.1080/09513590.2020.1821358</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09513590.2020.1821358</ArticleId><ArticleId IdType="pubmed">33078970</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T (2003) PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 198:39&#x2013;50. https://doi.org/10.1084/jem.20022235</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20022235</ArticleId><ArticleId IdType="pubmed">12847136</ArticleId><ArticleId IdType="pmc">2196084</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Bai J, Jiang T, Gao Y, Hua Y (2019) Modulation of PDCD1 exon 3 splicing. RNA Biol 16:1794&#x2013;1805. https://doi.org/10.1080/15476286.2019.1659080</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15476286.2019.1659080</ArticleId><ArticleId IdType="pubmed">31441370</ArticleId><ArticleId IdType="pmc">6844568</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez A, Montaudie H, Bory P, Belgodere X, Passeron T, Lacour JP, Picard A (2018) Antiphospholipid syndrome following pembrolizumab treatment of stage IIIB unresectable melanoma. JAMA Dermatol 154:1354&#x2013;1356. https://doi.org/10.1001/jamadermatol.2018.2770</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2018.2770</ArticleId><ArticleId IdType="pubmed">30326507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y, Honjo T, Tanaka Y, Minato N, Komori T, Maeda S, Kumagai S (2005) Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sj&#xf6;gren&#x2019;s syndrome. J Rheumatol 32:2156&#x2013;2163</Citation><ArticleIdList><ArticleId IdType="pubmed">16265694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukanxuan Wu, Lv C, Yifeng Su, Li C, Zhang H, Zhao X, Li M (2019) Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol. J Rheumatol 32:2156&#x2013;2163</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>